Net profit of Bafna Pharmaceuticals rose 19.08% to Rs 3.12 crore in the quarter ended September 2025 as against Rs 2.62 crore during the previous quarter ended September 2024. Sales declined 12.03% to Rs 35.47 crore in the quarter ended September 2025 as against Rs 40.32 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales35.4740.32 -12 OPM %12.049.42 - PBDT4.594.20 9 PBT3.122.62 19 NP3.122.62 19 Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News

Bafna Pharmaceuticals announced that the 30th Annual General Meeting(AGM) of the company will be held on 19 September 2025.Powered by Capital Market - Live News

Net profit of Bafna Pharmaceuticals reported to Rs 3.39 crore in the quarter ended June 2025 as against net loss of Rs 0.72 crore during the previous quarter ended June 2024. Sales rose 4.00% to Rs 34.62 crore in the quarter ended June 2025 as against Rs 33.29 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales34.6233.29 4 OPM %14.643.63 - PBDT4.761.07 345 PBT3.39-0.37 LP NP3.39-0.72 LP Powered by Capital Market - Live News

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live News